Long Non-coding RNA CYTOR Modulates Cancer Progression Through MiR-136-5p/MAT2B Axis in Renal Cell Carcinoma
Overview
Authors
Affiliations
Background: To explore the role of long noncoding RNAs (lncRNAs) cytoskeleton regulator RNA (CYTOR) in renal cell carcinoma (RCC).
Methods: The levels of CYTOR in RCC tissues and cell lines were detected by RT-qPCR. 786-O and Caki-1 cells were transfected with CYTOR-shRNA or pcDNA-CYTOR respectively, or co-transfected with CYTOR-shRNA and miR-136-5p inhibitor, or co-transfected with miR-136-5p mimic and pcDNA-MAT2B. MTT assay, Transwell assay and flow cytometry were used to evaluate cell proliferation, invasion and apoptosis. The relationship between lncRNA CYTOR and miRNA-136-5p was detected by dual luciferase reporter gene and RNA pull down assays, and the targeted relationship between miRNA-136-5p and MAT2B was verified by dual luciferase reporter gene assay. The interaction between MAT2B and BAG3 protein was verified by co-IP experiment. The role of lncRNA CYTOR in vivo was also examined.
Results: LncRNA CYTOR was up-regulated in RCC tissues and cell lines, and miR-136-5p was down-regulated in renal carcinoma cell lines and tissues. Downregulation of CYTOR inhibited cell proliferation and invasion and promoted apoptosis. miR-136-5p was sponged by lncRNA CYTOR, which negatively regulated the development of RCC. MAT2B was a target gene of miR-136-5p. MAT2B protein interacted directly with BAG3 protein to affect the proliferation, invasion and apoptosis of RCC cells. In vivo experiments showed that the expression level of miR-136-5p was increased, and MAT2B expression was decreased after CYTOR knockdown, thereby inhibiting the development of RCC.
Conclusions: LncRNA CYTOR promoted the progression of RCC by targeting miR-136-5p to regulate the target gene MAT2B, which interacted with BAG3 protein.
Farahani N, Alimohammadi M, Raei M, Nabavi N, Aref A, Hushmandi K J Cell Commun Signal. 2024; 18(4):e12054.
PMID: 39691874 PMC: 11647052. DOI: 10.1002/ccs3.12054.
Current insights and future directions of LncRNA Morrbid in disease pathogenesis.
Yang H, Gao J, Zheng Z, Yu Y, Zhang C Heliyon. 2024; 10(17):e36681.
PMID: 39263145 PMC: 11388785. DOI: 10.1016/j.heliyon.2024.e36681.
Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases.
Bravo-Vazquez L, Paul S, Colin-Jurado M, Marquez-Gallardo L, Castanon-Cortes L, Banerjee A Genes (Basel). 2024; 15(1).
PMID: 38275604 PMC: 10815231. DOI: 10.3390/genes15010123.
Qiu J, Wang Z, Zhao L, Zhang P, Xu Y, Xia Q Front Mol Biosci. 2023; 10:1201155.
PMID: 37529377 PMC: 10387556. DOI: 10.3389/fmolb.2023.1201155.
Wei H, Li Z, Zhao Y, Zhu S, Wen S, Quan C Cancer Rep (Hoboken). 2023; 6(8):e1824.
PMID: 37344930 PMC: 10432435. DOI: 10.1002/cnr2.1824.